BMO Capital analyst George Farmer initiated Exelixis with a Market Perform rating and $23 price target. The analyst believes Exelixis shares are “appropriately valued based on optimistic Street expectations for continued cabozantinib growth in renal cell carcinoma and hepatocellular carcinoma,” and would stay on the sidelines given the lack of near-term catalysts.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.